Categories October Surprise 2024 BioWorld Science May 6, 2024 Post author By Post date July 27, 2026 Schepens Eye Research Institute presented new preclinical data on its AAV2.sFasL gene therapy, an adeno-associated virus (AVV2) encoding soluble Fas ligand (sFasL) for the potential prevention of glaucoma.